ThirdRockV Profile Banner
Third Rock Ventures Profile
Third Rock Ventures

@ThirdRockV

Followers
6K
Following
421
Statuses
376

Boston, MA
Joined March 2016
Don't wanna be here? Send us removal request.
@ThirdRockV
Third Rock Ventures
3 months
Congratulations to @TraceNeuro on their launch with a $101M Series A! We are excited to support a team on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases.
@TraceNeuro
Trace Neuroscience
3 months
1 in 400 people around the world will be diagnosed w/ #ALS in their lifetime. Meet Trace - on a mission to expand the promise of genomic medicine for those w/ neurodegenerative diseases, re-establishing healthy communication between nerves & muscle cells.
0
0
5
@ThirdRockV
Third Rock Ventures
6 months
Great news for the @AbataTx team, patients, and their families!
@AbataTx
Abata Therapeutics
6 months
The FDA Fast Track designation for ABA-101 for the treatment of progressive MS will enable us to expedite our efforts to bring ABA-101 to patients. This advances our mission, as initiation of a first-in-human (FIH) Phase 1 study is imminent. #clinicaltrials
Tweet media one
0
0
2
@ThirdRockV
Third Rock Ventures
6 months
Congrats to the @moma_tx team! One step closer to helping oncology patients.
@moma_tx
MOMA Therapeutics
6 months
The 1st patient has been dosed in the Phase 1 clinical trial of MOMA-313, a novel, highly potent & selective oral POLq helicase inhibitor, & we've selected our 2nd development candidate, MOMA-341, an oral Werner helicase inhibitor. Read & learn more:
0
0
0
@ThirdRockV
Third Rock Ventures
6 months
We are excited by @AbataTx announcement today of a strategic investment from @bmsnews supporting advancement of its Treg cell therapies into clinical development. One step closer to positively impacting patients and their families.
@AbataTx
Abata Therapeutics
6 months
We are pleased to announce an equity #investment from @bmsnews to support the advancement of our #Treg cell therapies into clinical development. This investment marks a significant milestone as we prepare to initiate trials for ABA-101 in progressive multiple sclerosis:
Tweet media one
0
0
6
@ThirdRockV
Third Rock Ventures
10 months
Congratulations to Arnav Mehta for receiving the 2024 NextGen Stars award from AACR. So well deserved! @arnavmehta3
@MGHCancerCenter
Mass General Cancer Center
10 months
Arnav Mehta, MD, gastrointestinal oncologist, discusses new research for pancreatic cancer at #AACR24. Dr. Mehta received the 2024 NextGen Stars award for his research in pancreatic cancer at @AACR.
3
1
11
@ThirdRockV
Third Rock Ventures
1 year
We are delighted to announce the expansion of our senior team!
Tweet media one
1
1
13
@ThirdRockV
Third Rock Ventures
1 year
RT @LS_Cares: And we’re live! Check out the very first episode of our new podcast: Moving Forward, Giving Back. On today’s show, we highlig…
0
1
0
@ThirdRockV
Third Rock Ventures
1 year
Congrats to the team at @bluebirdbio ! Exciting news for patients and their families
@bluebirdbio
bluebird bio
1 year
#NewsfromtheNest: We are thrilled to announce that the @US_FDA has approved our first gene therapy for patients ages 12 and older living with sickle cell disease who have a history of vaso-occlusive events. Read more in our press release: [1/1]
2
0
10
@ThirdRockV
Third Rock Ventures
1 year
We had our first farmers market last week in our office to raise money for @LS_Cares and the Hope Lodge - @AmericanCancer! It was a fun time with tasty food to support two great causes.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
0
4
@ThirdRockV
Third Rock Ventures
1 year
Our collaboration with BrightEdge broadens the impact we can have across the oncology ecosystem. You can learn more about the great work they do below.
@AmericanCancer
American Cancer Society
1 year
BrightEdge is poised to impact the lives of over 1.5 million cancer patients through investments in cancer-focused therapies and technologies. To learn more, read the annual report:
0
1
3
@ThirdRockV
Third Rock Ventures
2 years
Third Rock is proud to partner with such an impactful organization!
@LS_Cares
Life Science Cares Boston
2 years
Thanks to an incredible list of sponsors and donors, the 2023 #TimmermanTraverse team has cracked their goal of raising $1M to support Life Science Cares' work in the community. And now they're aiming to see just how high they can go! Read more at
Tweet media one
0
0
5
@ThirdRockV
Third Rock Ventures
2 years
Congratulations! Great news for mothers and families.
@SageBiotech
Sage Therapeutics
2 years
BREAKING: The FDA has approved our new treatment, developed with @biogen, for women with #postpartumdepression. Learn more:
1
1
5
@ThirdRockV
Third Rock Ventures
2 years
Congratulations to the team at @Septerna_Inc !
@Septerna_Inc
@Septerna_Inc
2 years
Today we announced a $150M Series B financing, enabling the advancement of our lead program to clinical proof-of-mechanism and marking an important transition for our company. Read today’s news:
Tweet media one
0
1
1
@ThirdRockV
Third Rock Ventures
2 years
We had the pleasure of hosting an inspiring fireside chat with @TracyDixonSalaz and Brad Galer about rare epilepsies and Lennox-Gastaut Syndrome and the high unmet medical need in the precision neuromedicine space.
Tweet media one
0
0
12
@ThirdRockV
Third Rock Ventures
2 years
Please join us in welcoming Mary Lynne Hedley to TRV as our newest Venture Partner. She brings valuable leadership and strategic insight across R&D, operations, corporate strategy and business development. We are excited to have her as part of the team!
Tweet media one
0
1
11
@ThirdRockV
Third Rock Ventures
2 years
IgniteVC, a new initiative from @IgniteLC in partnership with @BioscienceGroup, has launched to accelerate DEI in life sciences VCs and their portfolio companies by offering practical tools, best practices, and a community of peers.
Tweet media one
0
3
7
@ThirdRockV
Third Rock Ventures
2 years
RT @AbataTx: Join us in welcoming Leonard Dragone, M.D., Ph.D., as our new Chief Medical Officer! (1 of 2) He is a drug developer with ext…
0
2
0
@ThirdRockV
Third Rock Ventures
2 years
Congrats to Rapport Therapeutics on the announcement of their launch with a $100 million Series A financing. Rapport is dedicated to the discovery and development of precision medicines for neurological disorders and we are excited to be a part of it!
1
2
11
@ThirdRockV
Third Rock Ventures
2 years
We are excited to be a Founding Partner in the expansion of @ProjectOnramp w/@LS_Cares to support + create paid summer internships for students who are under-resourced and under-represented, helping to bridge the opportunity gap into our industry.
@LS_Cares
Life Science Cares Boston
2 years
We’re on a mission to scale @ProjectOnramp to reach 1,000 students around the country each summer by 2027. Thanks to @ThirdRockV for this multi-year commitment to help us get there!
0
0
9
@ThirdRockV
Third Rock Ventures
2 years
0
0
2